HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Yidu Tech Inc - The Future Performance Is Worth Looking Forward To

Pre-IPO MicroPort CardioFlow - A Better Candidate of the TAVR Market in China?

Pre-IPO Bio-Thera Solutions - Insights on Pipeline and the Competitive Landscape

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

JBM Healthcare Ltd / Equity Capital Markets

<p>In 2020Q3, <a href="https://www.smartkarma.com/entities/jbm-healthcare-ltd" target="_blank" data-smartkarma-citation="entities:31085:1" rel="noopener">JBM Healthcare Ltd (1817825D HK)</a> applied to the Hong Kong Stock Exchange for a main board listing. JBM is a healthcare company headquartered in Hong Kong and a subsidiary of <a href="https://www.smartkarma.com/entities/jacobson-pharma" target="_blank" data-smartkarma-citation="entities:23579:1" rel="noopener">Jacobson Pharma (2633 HK)</a>. It is worth mentioning that another similar company, Tycoon Group (3390 HK) went public in 2020/1H. An indirect wholly-owned subsidiary of Jacobson participated in the HK$80m share subscription as a cornerstone investor. However, both Jacobson, which went public in 2016, and Tycoon Group, which went public in 2020, showed a volatile downward trend in the share price and didn’t perform well. This may be related to the limited growth potential in the industry, the lack of attractiveness, and the mediocre companies’ fundamentals. So could JBM break the ice?</p>

In 2020Q3, JBM Healthcare Ltd (1817825D HK) applied to the Hong Kong Stock Exchange for a main board listing. JBM is a healthcare company headquartered in Hong Kong and a subsidiary of Jacobson Pharma (2633 HK). It is worth mentioning that another similar company, Tycoon Group (3390 HK) went public in 2020/1H. An indirect wholly-owned subsidiary of Jacobson participated in the HK$80m share subscription as a cornerstone investor. However, both Jacobson, which went public in 2016, and Tycoon Group, which went public in 2020, showed a volatile downward trend in the share price and didn’t perform well. This may be related to the limited growth potential in the industry, the lack of attractiveness, and the mediocre companies’ fundamentals. So could JBM break the ice?

Pre-IPO JBM Healthcare Ltd. - Could JBM Break the Ice?